智通财经APP讯，中国生物制药(01177)发布公告，集团将在2026年中国临床肿瘤学会(CSCO)学术年会公布21项最新研究成果，其中包含5项口头报告。研究涉及在研项目TQB3454(IDH1抑制剂)，以及已上市产品安罗替尼胶囊(商品名：福可维® )、贝莫苏拜单抗注射液(商品名：安得卫® )、艾贝格司亭α注射液(商品名：亿立舒® )、派安普利单抗注射液(商品名：安尼可® )，覆盖胰腺癌、肺癌、肾细胞癌、消化道肿瘤、软组织肉瘤、甲状腺癌、乳腺癌等多个治疗领域。
智通财经APP讯，中国生物制药(01177)发布公告，集团将在2026年中国临床肿瘤学会(CSCO)学术年会公布21项最新研究成果，其中包含5项口头报告。研究涉及在研项目TQB3454(IDH1抑制剂)，以及已上市产品安罗替尼胶囊(商品名：福可维® )、贝莫苏拜单抗注射液(商品名：安得卫® )、艾贝格司亭α注射液(商品名：亿立舒® )、派安普利单抗注射液(商品名：安尼可® )，覆盖胰腺癌、肺癌、肾细胞癌、消化道肿瘤、软组织肉瘤、甲状腺癌、乳腺癌等多个治疗领域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.